By NextBestFitHarm reduction services
Fund naloxone, drug checking, and supervised consumption sites.
Fewer deaths; community opposition.
To review: Supervised consumption sites are contested.
Review ledgerHow this path connects
This path
Harm reduction services
Creates or worsens
Concrete changes if chosen
What would actually have to change in law, agencies, payment rules, or systems.
- Fund naloxone, drug checking, and supervised consumption sites
Effects
Each effect has its own page: the evidence, the case that it is or isn't a real cost, and whom it affects.
What it fixes
- Overdose crisis and gaps in addiction treatment
Funding naloxone, drug checking, and supervised consumption sites reduces deaths and connects people to treatment.
What it creates or worsens
- Faces political, industry, or legal opposition
Supervised consumption sites and other harm reduction services face community opposition and legal uncertainty.
Who's affected
Who gains
- People with substance use disorders and affected communities
- Overdose crisis and gaps in addiction treatment: Overdoses, treatment restrictions, and coverage gaps harm people and their families.
- Family caregivers and affected families
- Overdose crisis and gaps in addiction treatment: Overdoses, treatment restrictions, and coverage gaps harm people and their families.
Who loses
- Hospitals, clinics, and care organizations
- Overdose crisis and gaps in addiction treatment: Unregulated treatment operators benefit from the treatment system’s gaps.
- Fraudulent operators and cybercriminals
- Overdose crisis and gaps in addiction treatment: Illicit drug markets benefit from ongoing substance use.
Other ways to soften the losses
- Site selection with community input
Where it has been tried
- Portugal, Canada: Harm reduction plus treatment.
- Canada (Vancouver): In Canada (2011), a Lancet study found fatal drug overdoses dropped by 35% within 500 meters of Vancouver’s supervised injection site after it opened, compared to a 9% decline across the rest of the city.Sources: The Lancet (2011)